Latest & greatest articles for infliximab

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on infliximab or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on infliximab and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for infliximab

61. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation

Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation Journals Library An error has occurred in processing the XML document An error occurred

NIHR HTA programme2011

62. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation

Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation Journals Library An error has occurred in processing the XML document An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose

NIHR HTA programme2011

63. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-a) inhibitors, adalimumab and infliximab, for Crohn?s disease

A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-a) inhibitors, adalimumab and infliximab, for Crohn?s disease A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-a) inhibitors, adalimumab and infliximab, for Crohn's disease Journals Library An error has occurred in processing the XML document An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry

NIHR HTA programme2011

64. Remicade (Infliximab Janssen Biotech Inc., a Johnson&Johnson Company) for treatment of pulmonary sarcoidosis)

Remicade (Infliximab Janssen Biotech Inc., a Johnson&Johnson Company) for treatment of pulmonary sarcoidosis) Remicade (Infliximab; Janssen Biotech Inc., a Johnson&Johnson Company) for treatment of pulmonary sarcoidosis Remicade (Infliximab; Janssen Biotech Inc., a Johnson&Johnson Company) for treatment of pulmonary sarcoidosis Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA (...) database. Citation Remicade (Infliximab; Janssen Biotech Inc., a Johnson&Johnson Company) for treatment of pulmonary sarcoidosis . Lansdale: HAYES, Inc.. Healthcare Technology Brief Publication Dates. 2011 Authors' conclusions Sarcoidosis is an inflammatory multisystem disorder of unknown etiology that is characterized by the development of noncaseating granulomas (collections of immune cells and other cells) in one or more organ systems. In theory, the disorder is believed to be the result

Health Technology Assessment (HTA) Database.2011

65. Remicade (Infliximab Janssen Biotech Inc., a Johnson&Johnson Company) for treatment of neurosarcoidosis)

Remicade (Infliximab Janssen Biotech Inc., a Johnson&Johnson Company) for treatment of neurosarcoidosis) Remicade (Infliximab; Janssen Biotech Inc., a Johnson&Johnson Company) for treatment of neurosarcoidosis Remicade (Infliximab; Janssen Biotech Inc., a Johnson&Johnson Company) for treatment of neurosarcoidosis Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation (...) Remicade (Infliximab; Janssen Biotech Inc., a Johnson&Johnson Company) for treatment of neurosarcoidosis . Lansdale: HAYES, Inc.. Healthcare Technology Brief Publication Dates. 2011 Authors' conclusions Sarcoidosis is an inflammatory multisystem disorder of unknown etiology that is characterized by the development of noncaseating granulomas (collections of immune cells and other cells) in one or more organ systems. The incidence peaks between the second and third decades of life, with another peak

Health Technology Assessment (HTA) Database.2011

66. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation

Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation Rodgers M, Epstein D, Bojke L, Yang H, Craig D, Fonseca T, Myers L, Bruce I, Chalmers R, Bujkiewicz S, Lai M, Cooper N, Abrams (...) K, Spiegelhalter D, Sutton A, Sculpher M, Woolacott N Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Rodgers M, Epstein D, Bojke L, Yang H, Craig D, Fonseca T, Myers L, Bruce I, Chalmers R, Bujkiewicz S, Lai M, Cooper N, Abrams K, Spiegelhalter D, Sutton A, Sculpher M, Woolacott N. Etanercept, infliximab and adalimumab for the treatment

Health Technology Assessment (HTA) Database.2011

67. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor: a systematic review and economic evaluation

Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor: a systematic review and economic evaluation Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor: a systematic review and economic evaluation Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF (...) , etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor: a systematic review and economic evaluation . Health Technology Assessment 2011; 15(14): 1-278 Authors' conclusions Study found rituximab and abatacept to be more effective compared with supportive care (including ongoing disease-modifying antirheumatic drugs) in rheumatoid arthritis after failure of a TNF inhibitor. Use of an alternative TNF inhibitor in this patient population

Health Technology Assessment (HTA) Database.2011

68. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-a) inhibitors, adalimumab and infliximab, for CrohnÔ??s disease

A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-a) inhibitors, adalimumab and infliximab, for CrohnÔ??s disease A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-a) inhibitors, adalimumab and infliximab, for Crohn's disease A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-a) inhibitors, adalimumab and infliximab, for Crohn's disease Dretzke J, Edlin R, Round J (...) , Connock M, Hulme C, Czeczot J, Fry-Smith A, McCabe C, Meads C Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Dretzke J, Edlin R, Round J, Connock M, Hulme C, Czeczot J, Fry-Smith A, McCabe C, Meads C. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-a) inhibitors, adalimumab and infliximab, for Crohn's

Health Technology Assessment (HTA) Database.2011

69. Cost effectiveness of two therapeutic regimens of infliximab in ankylosing spondylitis: economic evaluation within a randomised controlled trial

Cost effectiveness of two therapeutic regimens of infliximab in ankylosing spondylitis: economic evaluation within a randomised controlled trial 19740900 2010 01 28 2010 02 19 2015 11 19 1468-2060 69 2 2010 Feb Annals of the rheumatic diseases Ann. Rheum. Dis. Cost effectiveness of two therapeutic regimens of infliximab in ankylosing spondylitis: economic evaluation within a randomised controlled trial. 424-7 10.1136/ard.2008.103887 To determine the incremental cost-effectiveness ratios (ICERs (...) ) of two therapeutic regimens of infliximab for ankylosing spondylitis (AS). 230 patients with active AS who were participating in a randomised controlled trial comparing two infliximab infusion modalities-every 6 weeks (Q6) and on demand (DEM)-were included in an economic evaluation within the trial. Data were collected by phone every 3 months for 1 year. Direct and indirect costs were calculated from a payer perspective. Health-related quality of life was assessed with a general health rating scale

EvidenceUpdates2010

70. Cross-sectional: Severe adverse reactions are rare with infusions of infliximab in a community setting

Cross-sectional: Severe adverse reactions are rare with infusions of infliximab in a community setting Severe adverse reactions are rare with infusions of infliximab in a community setting | Evidence-Based Nursing This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search (...) for this keyword Search for this keyword Main menu Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Severe adverse reactions are rare with infusions of infliximab in a community setting Article Text Prevalence Cross-sectional Severe adverse reactions are rare with infusions of infliximab in a community setting Yusuf Yazici Statistics from Altmetric.com No Altmetric data

Evidence-Based Nursing (Requires free registration)2010

71. Cost-effectiveness of scheduled maintenance treatment with infliximab for pediatric Crohn's disease

Cost-effectiveness of scheduled maintenance treatment with infliximab for pediatric Crohn's disease Cost-effectiveness of scheduled maintenance treatment with infliximab for pediatric Crohn's disease Cost-effectiveness of scheduled maintenance treatment with infliximab for pediatric Crohn's disease Punekar YS, Sunderland T, Hawkins N, Lindsay J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief (...) summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study investigated the cost-effectiveness of infliximab, compared with standard care, as maintenance therapy for paediatric patients with moderate-to-severe Crohn’s disease. The authors concluded that infliximab was likely to be cost-effective compared with standard care. There were limited data available, but the methods appear

NHS Economic Evaluation Database.2010

72. Infliximab for maintenance therapy for treatment of crohn's disease: a review of the clinical effectiveness and guidelines

Infliximab for maintenance therapy for treatment of crohn's disease: a review of the clinical effectiveness and guidelines Infliximab for maintenance therapy for treatment of Crohn's disease: a review of the clinical effectiveness and guidelines Infliximab for maintenance therapy for treatment of Crohn's disease: a review of the clinical effectiveness and guidelines Canadian Agency for Drugs and Technologies in Health Record Status This is a bibliographic record of a published health technology (...) assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Canadian Agency for Drugs and Technologies in Health. Infliximab for maintenance therapy for treatment of Crohn's disease: a review of the clinical effectiveness and guidelines. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2010 Authors' conclusions Observational studies have reported that response to infliximab is regained after the dose is increased

Health Technology Assessment (HTA) Database.2010

73. Meta-analysis: pre-operative infliximab treatment and short-term post-operative complications in patients with ulcerative colitis

Meta-analysis: pre-operative infliximab treatment and short-term post-operative complications in patients with ulcerative colitis Meta-analysis: pre-operative infliximab treatment and short-term post-operative complications in patients with ulcerative colitis Meta-analysis: pre-operative infliximab treatment and short-term post-operative complications in patients with ulcerative colitis Yang Z, Wu Q, Wu K, Fan D CRD summary The review found that preoperative infliximab appeared to increase (...) short-term postoperative complications among patients with ulcerative colitis, possibly due to an increased risk of postoperative infection. In view of limitations in the review, including a suboptimal search, lack of randomised studies, failure to report study quality, and wide differences between the studies, the authors’ conclusions may not be reliable. Authors' objectives To assess the effect of preoperative infliximab on short-term postoperative complications among patients with ulcerative

DARE.2010

74. Cost-effectiveness of infliximab for the treatment of acute exacerbations of ulcerative colitis

Cost-effectiveness of infliximab for the treatment of acute exacerbations of ulcerative colitis Cost-effectiveness of infliximab for the treatment of acute exacerbations of ulcerative colitis Cost-effectiveness of infliximab for the treatment of acute exacerbations of ulcerative colitis Punekar YS, Hawkins N Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The aim was to assess the cost-effectiveness of infliximab for patients hospitalised with acute exacerbations of ulcerative colitis. The authors concluded that infliximab was a cost-effective treatment for these patients. The methods and the reporting of study were satisfactory and the results appear to be reliable. Type of economic evaluation Cost-utility analysis Study objective

NHS Economic Evaluation Database.2010

75. Cost-effectiveness of real-world infliximab use in patients with rheumatoid arthritis in Sweden

Cost-effectiveness of real-world infliximab use in patients with rheumatoid arthritis in Sweden Cost-effectiveness of real-world infliximab use in patients with rheumatoid arthritis in Sweden Cost-effectiveness of real-world infliximab use in patients with rheumatoid arthritis in Sweden Lekander I, Borgstrom F, Svarvar P, Ljung T, Carli C, van Vollenhoven RF Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract (...) contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to assess the cost-effectiveness of infliximab for the treatment of rheumatoid arthritis. The authors concluded that infliximab treatment provided good value for money in Swedish clinical practice. There were some limitations to the analysis and reporting, which means that the conclusions reached

NHS Economic Evaluation Database.2010

76. Use of anti-infliximab antibody levels to monitor infliximab treatment

Use of anti-infliximab antibody levels to monitor infliximab treatment Use of anti-infliximab antibody levels to monitor infliximab treatment Use of anti-infliximab antibody levels to monitor infliximab treatment Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Use of anti-infliximab antibody levels to monitor infliximab treatment. Lansdale: HAYES, Inc (...) there is no cure for rheumatoid arthritis, treatment is focused on relieving inflammation and pain and preventing joint destruction. In patients who do not respond adequately to anti-inflammatory, immunosuppressive, and antirheumatic drugs, genetically engineered biological agents such as infliximab have been developed that block the action of specific proteins that promote inflammation. Infliximab (Remicade, Centocor Ortho Biotech Inc.) is a genetically engineered antibody that binds to the protein tumor

Health Technology Assessment (HTA) Database.2010

77. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab

Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab 19596014 2009 10 05 2009 10 15 2015 11 19 1528-0012 137 4 2009 Oct Gastroenterology Gastroenterology Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. 1250-60; quiz 1520 10.1053/j.gastro.2009.06.061 The efficacy of infliximab for treating patients with ulcerative colitis has been established. The Active Ulcerative Colitis Trial (ACT)-1 and ACT-2 randomized, double (...) -blind, placebo-controlled studies evaluated infliximab induction and maintenance therapy in moderately to severely active ulcerative colitis. Overall, 728 patients received placebo or infliximab (5 or 10 mg/kg) intravenously at weeks 0, 2, and 6, then every 8 weeks through week 46 (ACT-1) or 22 (ACT-2). Colectomy, hospitalization, and surgery/procedure data through 54 weeks after the first infusion were obtained from ACT-1, ACT-2, and associated data sources. In the prespecified analysis, all data

EvidenceUpdates2010

78. Infliximab, azathioprine, or combination therapy for Crohn's disease.

Infliximab, azathioprine, or combination therapy for Crohn's disease. 20393175 2010 04 15 2010 04 22 2015 11 19 1533-4406 362 15 2010 Apr 15 The New England journal of medicine N. Engl. J. Med. Infliximab, azathioprine, or combination therapy for Crohn's disease. 1383-95 10.1056/NEJMoa0904492 The comparative efficacy and safety of infliximab and azathioprine therapy alone or in combination for Crohn's disease are unknown. In this randomized, double-blind trial, we evaluated the efficacy (...) of infliximab monotherapy, azathioprine monotherapy, and the two drugs combined in 508 adults with moderate-to-severe Crohn's disease who had not undergone previous immunosuppressive or biologic therapy. Patients were randomly assigned to receive an intravenous infusion of 5 mg of infliximab per kilogram of body weight at weeks 0, 2, and 6 and then every 8 weeks plus daily oral placebo capsules; 2.5 mg of oral azathioprine per kilogram daily plus a placebo infusion on the standard schedule; or combination

NEJM2010

79. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (TA195)

Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (TA195) Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor | Guidance and guidelines | NICE Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor Technology appraisal guidance [TA195 (...) ] Published date: 25 August 2010 Share Guidance on adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade), rituximab (MabThera) and abatacept (Orencia). These drugs are for adults with severe rheumatoid arthritis who have tried other disease-modifying antirheumatic drugs (DMARDs) but cannot tolerate them or they haven’t worked well enough. The recommendations also apply to biosimilar products of these technologies that have a marketing authorisation allowing the use of the biosimilar for the same

National Institute for Health and Clinical Excellence - Technology Appraisals2010

80. Infliximab (review) and adalimumab for the treatment of Crohn's disease (TA187)

Infliximab (review) and adalimumab for the treatment of Crohn's disease (TA187) Infliximab and adalimumab for the treatment of Crohn's disease | Guidance and guidelines | NICE Infliximab and adalimumab for the treatment of Crohn's disease Technology appraisal guidance [TA187] Published date: 19 May 2010 Share Guidance on infliximab (Remicade) and adalimumab (Humira) for treating severe active Crohn's disease in adults. The recommendations also apply to biosimilar products of the technologies (...) that have a marketing authorisation allowing the use of the biosimilar for the same indication. This guidance replaces NICE technology appraisal guidance on the clinical effectiveness and cost effectiveness of infliximab for Crohn's disease (TA40). Guidance development process Is this guidance up to date? . We found nothing new that affects the recommendations in this guidance. Next review : This guidance will be reviewed if there is new evidence that is likely to affect the recommendations. Your

National Institute for Health and Clinical Excellence - Technology Appraisals2010